Monument Capital Management acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,888 shares of the medical research company’s stock, valued at approximately $222,000.
Other hedge funds have also recently bought and sold shares of the company. American National Bank increased its position in Edwards Lifesciences by 99.1% during the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $29,000. Rinkey Investments purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $29,000. Northwest Investment Counselors LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $30,000. Finally, Arlington Partners LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter valued at $34,000. Institutional investors and hedge funds own 82.54% of the company’s stock.
In other news, VP Larry L. Wood sold 7,242 shares of Edwards Lifesciences stock in a transaction on Tuesday, April 5th. The stock was sold at an average price of $121.03, for a total transaction of $876,499.26. Following the transaction, the vice president now owns 197,641 shares in the company, valued at approximately $23,920,490.23. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,050 shares of Edwards Lifesciences stock in a transaction on Friday, April 8th. The stock was sold at an average price of $123.34, for a total value of $1,362,907.00. Following the transaction, the vice president now owns 152,326 shares in the company, valued at approximately $18,787,888.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 204,165 shares of company stock worth $21,328,796. 1.29% of the stock is currently owned by corporate insiders.
Edwards Lifesciences (NYSE:EW – Get Rating) last announced its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.02. Edwards Lifesciences had a net margin of 28.72% and a return on equity of 25.80%. The company had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the company posted $0.54 EPS. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.
A number of analysts have recently issued reports on the stock. Citigroup lowered their target price on shares of Edwards Lifesciences from $134.00 to $115.00 and set a “buy” rating for the company in a research note on Tuesday, May 17th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $132.00 to $135.00 in a research report on Wednesday, March 16th. Canaccord Genuity Group cut their target price on shares of Edwards Lifesciences from $152.00 to $137.00 in a report on Wednesday, April 27th. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a report on Tuesday, April 26th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. Four investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $128.86.
About Edwards Lifesciences (Get Rating)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- It’s A Comfortable Time To Buy Steelcase
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.